Chartwell Investment Partners, LLC Iovance Biotherapeutics, Inc. Transaction History

Chartwell Investment Partners, LLC

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Oct 27, 2022	BUY	$9.53 - $13.11 $15,581 - $21,434	1,635 Added 3.63%	46,672 $447,000
Q2 2022 Aug 01, 2022	BUY	$6.38 - $18.33 $287,336 - $825,528	45,037 New	45,037 $497,000
Q4 2021 Feb 15, 2022	SELL	$16.55 - $27.63 $1.01 Million - $1.68 Million	-60,750 Closed	0 $0
Q3 2021 Nov 16, 2021	BUY	$20.35 - $26.63 $250,834 - $328,241	12,326 Added 25.45%	60,750 $1.5 Million
Q2 2021 Jul 19, 2021	BUY	$16.33 - $33.07 $790,763 - $1.6 Million	48,424 New	48,424 $1.26 Million
Q4 2020 Feb 09, 2021	SELL	$28.04 - $50.26 $915,029 - $1.64 Million	-32,633 Closed	0 $0
Q2 2020 Jul 29, 2020	SELL	$27.21 - $41.0 $943,207 - $1.42 Million	-34,664 Reduced 51.51%	32,633 $896,000
Q1 2020 Apr 30, 2020	BUY	$19.54 - $38.85 $142,016 - $282,361	7,268 Added 12.11%	67,297 $2.02 Million
Q4 2019 Jan 29, 2020	SELL	$17.95 - $29.41 $414,214 - $678,665	-23,076 Reduced 27.77%	60,029 $1.66 Million
Q3 2019 Oct 29, 2019	SELL	$17.99 - $26.0 $942,604 - $1.36 Million	-52,396 Reduced 38.67%	83,105 $1.51 Million
Q2 2019 Aug 19, 2019	BUY	$9.78 - $24.52 $1.33 Million - $3.32 Million	135,501 New	135,501 $3.32 Million

342

247M

2.51M

3.5M

Ticker IOVA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 157,800,992
Market Cap $573M
Description
Iovance Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing cancer immunotherapy products to harness the power of a patient's immune system to eradicate cancer cells. It has six ongoing phase 2 clinical studies, including C-144-01, of its lead product candidate, lifileucel, for the treatment o...

Get notified when there are updates to the investment portfolio of Chartwell Investment Partners, LLC, based on Form 13F filings with the SEC.

Stay updated on Chartwell Investment Partners, LLC with notifications on news.